INTRODUCTION {#sec1-1}
============

Temporomandibular disorders (TMDs) are a group of increasingly frequent disorders with multifactorial etiology. The most common risk factors are depression, pain elsewhere in the body, clenching, onychophagia, emotional and physical traumas, dental microtraumas, temporomandibular joint (TMJ) hypermobility, time-consuming dental treatments, somatic symptom disorders, and diseases compromising TMJ function.\[[@ref1][@ref2][@ref3][@ref4]\] The condition comprises a group of signs and symptoms reflecting alterations in TMJ function, mastication muscles, and related structures, and is mainly characterized by the presence of pain, joint sounds, and irregular or limited jaw function.\[[@ref4][@ref5][@ref6][@ref7]\]

Multiple sclerosis (MS) is a chronic, inflammatory, progressive, degenerative, and disabling neurological disease affecting the central nervous system. The disease is marked by attacks to the myelin sheath covering the axons, which are induced by specialized cells of the immune system --T-helper lymphocytes Types 1 and 17. For that reason, MS is considered an autoimmune disease, in which humoral immunity also plays a role as immunoglobulins are found in the cerebrospinal fluid of patients with MS. The pathogenesis of MS is heterogeneous, and its biological markers have not been elucidated to date.\[[@ref8][@ref9][@ref10][@ref11]\] MS is predominantly found in populations of temperate and cold climate zones, with prevalence reaching 200/100,000 population. In Brazil, the prevalence of MS is around 15/100,000.\[[@ref12][@ref13]\] Some of the clinical manifestations of interest to dentistry are trigeminal neuralgia, facial palsy, trigeminal sensory neuropathy, and TMDs.\[[@ref14][@ref15]\]

Various studies\[[@ref14][@ref15][@ref16][@ref17][@ref18]\] have identified TMD in patients with MS. It has been hypothesized that cerebellar ataxia and proprioceptive alterations lead to increased susceptibility to TMD. However, there is a paucity of studies clarifying the relationship between TMD and MS or relating different degrees of MS disability based on the Expanded Disability Status Scale (EDSS)\[[@ref19]\] to TMD symptoms. The objectives of the present study were to assess the prevalence of TMD in patients with MS, compared those patients with a control group (CG), and determine the relationship between the degree of disability of patients with MS (EDSS) and the presence of TMD.

MATERIALS AND METHODS {#sec1-2}
=====================

The present investigation was approved by the Institutional Review Board of the University Federal Fluminense (UFF). It consisted of a cross-sectional, observational, controlled, and open study of 120 individuals at the Hospital University Antonio Pedro (HUAP/UFF), with and without MS, to determine the prevalence of TMD symptoms and possible subtypes in patients seen between January 2015 and August 2016. The MS group comprised 60 consecutive individuals with a diagnosis of relapsing-remitting type MS recruited from the HUAP-UFF neurology outpatient clinic. The study included male or female patients aged 18-80 years diagnosed according to the McDonald criteria\[[@ref20]\] as relapsing-remitting MS, with any EDSS score, who were receiving regular medical care at the neurology clinic and provided written informed consent. The CG, matched for sex and age, included 60 individuals attending the same outpatient clinic as chaperones or family members of the MS group participants. The control individuals had no diagnosis of MS or any neurological disease such as idiopathic inflammatory-demyelinating diseases and provided written informed consent.

Individuals of both groups were excluded if they declined to provide written informed consent or had cognitive deficits.

The investigation was conducted in one individual session in which the respondent\'s demographic data were recorded on a chart. The EDSS is the most used rating system to determine the severity and progression of MS. EDSS is based on functional systems as follows: pyramidal, cerebellar, brain stem, sensory, sphincters, visual, mental, and other. The EDSS score ranges from 0 to 10, higher scores meaning more disability.\[[@ref19]\] The data pertaining to MS and respective neurological EDSS-based, impairment were verified by two or more of the clinic neurologists.

A questionnaire recommended by the EACD\[[@ref21]\] was used to identify TMD symptoms. The screening protocol includes four questions:

Do you have pain when you open your mouth wide or chew once a week or more?Do you have pain in your temples, face, temporomandibular joint, or jaws once a week or more?Have you recently registered that the jaw is locked or that you cannot open wide?Do you have often headache more than once a week?

If the patient replies yes to one of the four questions, a more thorough history taking and assessment may be indicated.

The RDC/TMD Axis I\[[@ref22]\] instrument provided an important first step toward an etiology-based system. It was administered whenever an affirmative answer was given by individuals of either group (case or control) to at least one of the four screening questions. The questionnaires were administered by one of the investigators in charge of the study, exclusively.

Fisher\'s exact test was used for the statistical analysis, with 2 × 2 contingency tables constructed to compare two nonparametric groups. ANOVA was used to detect significant differences between means and to assess whether the factors influenced any of the dependent variables by comparing means from the different groups.

Statistical significance was set at *P* \< 0.05.

RESULTS {#sec1-3}
=======

Gender distribution was 45 (75%) females and 15 (25%) males for both groups.

Age in the MS group ranged between 21 and 79 years (mean, 4.1 ± 10.8 years) versus 22-70 years (mean, 43.7 ± 11.93 years) in the CG. There was no significant difference between groups (ANOVA, *P* = 0.75).

TMD symptoms were significantly more frequent in the MS group (37 patients, 61.7%) compared to the control (11 individuals, 18.3%) (Fisher\'s exact, *P* = 0.0001) \[Tables [1](#T1){ref-type="table"}--[5](#T5){ref-type="table"}\].
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Distribution of individuals according to the answer to the question 2
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Distribution of individuals according to the answer to the question 3
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Distribution of individuals according to the answer to the question 4
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Distribution of individuals according to the answer to the four questions
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A significant difference was found between groups (Fisher\'s exact, *P* = 0.0001) with regard to the RDC/TMD assessment \[[Table 6](#T6){ref-type="table"}\]. Muscle-type TMD (myofascial pain with or without jaw opening limitation) accounted for 54.5% (12 patients), while joint-related TMD was found in 9.1% (2 patients), and the combined subtype in 36.4% (8 patients).

###### 

Distribution of individuals according to research diagnostic criteria/temporomandibular disorder evaluation
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There was a statistically significant difference between the group with milder MS and the group with more severe disease (Fisher\'s exact, *P* = 0.0288) with regard to the presence of TMD, as shown in [Table 7](#T7){ref-type="table"}.

###### 

Proportion of temporomandibular disorder diagnosis in the multiple sclerosis group relative to Expanded Disability Status Scale scores
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DISCUSSION {#sec1-4}
==========

The groups in the present study were gender- and age-matched, with a mean age of approximately 43 years and 75% of females. Symptoms of TMD were noted in 61.7% of the MS group and only in 18.3% of the CG, while a diagnosis of TMD was made for 36.7% in the MS group and 3.3% in the control. Myofascial pain TMD was diagnosed in 54.5% of patients in the MS group; the severity of MS was not proportional to the presentation of TMD in that group.

According to the literature,\[[@ref14][@ref17][@ref18]\] both MS and TMD are more prevalent in young adult females.

Symons *et al*. recorded the history and performed a clinical examination on 22 patients with MS; however, the patient group was small, and there was no control.\[[@ref17]\] Kovac *et al*. evaluated a larger group: 50 patients with MS and 50 controls.\[[@ref14]\] Two studies reported only one case each, and neither was methodologically robust to confirm or dismiss a relationship between TMD and MS.\[[@ref15][@ref16]\] Danesh-Sani *et al*.\[[@ref18]\] did not compare MS patients with a CG, yet they were able to study a considerably large sample: 500 patients with MS. The present study included a smaller sample (60 patients with MS and 60 controls) compared to that of

Danesh-Sani *et al*.,\[[@ref18]\] which can be explained by the difficulty in finding patients with MS in Brazil, given the very low prevalence rate compared to northern hemisphere countries.

Tweedle *et al*.\[[@ref16]\] reported a case based on the patient\'s history and clinical examination including TMJ palpation. Badel *et al*.\[[@ref15]\] also reported a single case, in which they used RDC/TMD as the diagnostic tool. Symons *et al*.\[[@ref17]\] used history-taking followed by palpation of the TMJ and masticatory muscles for TMD diagnosis, but employed no validated criteria to establish the diagnosis. Kovac *et al*.\[[@ref14]\] and Danesh-Sani *et al*.\[[@ref18]\] conducted their assessments using the RDC/TMD, which is a validated instrument for TMD diagnosis. In the present study, in addition to the RDC/TMD, the EACD questionnaire, a standardized measure for TMD symptom assessment, and the EDSS, a measure of MS-related disability, were used. Neither was used in the aforementioned studies.

In the assessment of TMD symptoms, the present study showed a statistically significant difference between the MS and CGs, with the MS group manifesting more TMD symptoms compared to the control. It was found that 61.7% of the MS patients had at least one TMD symptom compared to only 18.3% in the CG. These findings are comparable to those of the study by Symons *et al*.,\[[@ref17]\] which identified TMD symptoms in 40.9% of the patients. However, their study had no CG. In the controlled study by Kovac *et al*.,\[[@ref14]\] the difference was also significant, with 82% for the MS group and 24% for the control. Unlike the present study, those authors considered joint sounds as TMD symptoms, which could account for the difference between the two studies. This hypothesis was further supported by the fact that 30% of the patients with MS and 10% in the CG were found to have joint sounds in the study by Kovac *et al*.\[[@ref14]\] However, their study did not report the number of patients who manifested joint sounds in conjunction with other symptoms and how many had joint sounds like the only presenting symptom, which makes it difficult to determine the exact frequency of symptoms.

The study by Danesh-Sani *et al*.\[[@ref18]\] did not report which TMD symptoms were found.

In the present study, pain on jaw movements was noted in 11.7% of the patients with MS and 5% in the CG, whereas 31.8% of the patients in the study by Symons *et al*.\[[@ref17]\] had those symptoms. Kovac *et al*.\[[@ref14]\] reported pain during jaw movements in 22% of the MS group versus 4% in the CG.

Pain in the face, temples, TMJ, or maxilla occurred in 45% of the MS group and 6.7% in the CG. These findings are similar to those of Symons *et al*.,\[[@ref17]\] as 40.9% of the patients with MS in their study complained of TMJ and facial pain, and to those of Kovac *et al*.,\[[@ref14]\] who reported facial and TMJ pain in 54% of the patients with MS compared to 10% in the CG.

The present study identified closed lock in 15% of the MS group and 3.3% of controls. These results are comparable to those of Kovac *et al*.,\[[@ref14]\] who found closed lock in 22% of the patients with MS and 0% in the CG.

Headaches were found in 48.3% of the MS group and 16.7% controls in the present study. No other study reported that symptom.

It is worth noting that the presence of TMD symptoms alone does not necessarily translate into a diagnosis of the disorder. In the present study, TMD was diagnosed in 36.7% of the patients with MS and 3.3% of controls --comparable rates to those found by Kovac *et al*.,\[[@ref14]\] as 44.4% in their study were given a diagnosis of TMD in the MS group and 4% in the CG. In the study by Danesh-Sani *et al*.,\[[@ref18]\] 58.2% of the patients had TMD. Regarding the TMD subtype in patients with MS, Kovac *et al*.\[[@ref14]\] reported a 72% prevalence of TMD with myofascial pain. In the present study, 54.5% had myofascial pain involvement exclusively, while joint-related TMD was found in 9.1%, and combined TMD accounted for 36.4% of cases. The other studies made no mention of TMD subtypes.

None of the referenced studies related the degree of disability from MS based on the EDSS to the presence of TMD. In the present study, there was a significant difference in EDSS scores for patients with TMD (*P* = 0.0288). It was found that the lower the EDSS, the greater the prevalence of TMD.

One limitation of the present study was the sample size, as a larger sample could allow for more robust results. Another shortcoming was the lack of follow-up, as is true for all cross-sectional studies.

A more thorough analysis evaluating the scores for each function on the EDSS and relating those scores to the presence of TMD could enable further elucidation.

Finally, the inclusion of other CGs such as patients with the primary progressive or secondary progressive type of MS would also open the way to major insights on this subject.
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